Rheumatology Roundtable: Axial spondyloarthritis guideline (2025)

The latest evidence-based clinical guideline for axial spondyloarthritis (axSpA) features updated recommendations on biologic and targeted synthetic DMARDs, plus a strong focus on non-pharmacological treatments. Hear directly from experts in our Rheumatology Roundtable as they break down what's new, what matters, and how this guideline update will impact everyday clinical practice. Access the guideline: https://rheumatology.org.uk/guidelines.

In this video:
1:48 Karl's overview of the guideline, why an updated was needed and what is new
3:28 Stephanie's explanation of how the guideline was developed
6:52 Steven's overview of some of the key recommendations and how they differ from the previous version of the guideline
9:24 Dale's explanation of how he and other experts by experience were involved in the guideline’s development
10:31 Dale covers what the guideline means for patients and how will it benefit people with axSpA
11:12 Will outlines how the updated guideline can be used by himself and other AHPs
13:33 Will describes the key things in the guideline for people in primary care to take away
14:29 Karl explains why multi-speciality involvement in the guideline update was important and the recommendations we see in the guideline as a result
15:59 All panellists highlighting how listeners and readers of the guideline can be supported to ensure recommendations are implemented into clinical practice

Chair:
Ernest Choy, Editor in Chief, Rheumatology Journal

Panellists:
Karl Gaffney – Consultant rheumatologist, Norfolk & Norwich University Hospital NHS Foundation Trust
William Gregory – Physiotherapist, Salford Royal
Stephanie Harrison – Rheumatologist (trainee), Lead Author, University of Leeds
Dale Webb – Patient representative, NASS
Steven Zhao – Rheumatologist (trainee), Lead Author, University of Manchester